In a randomized multicenter study, the efficacy and safety of cefprozil were compared with those of penicillin in the treatment of group A streptococcal tonsillopharyngitis in children. Of the 409 patients enrolled, 323 were evaluable for their clinical and bacteriological responses; of these 323 children, 172 received cefprozil and 151 received penicillin V. The clinical responses in patients treated with cefprozil were significantly better than those in patients who received penicillin (95.3 versus 88.1%; P = 0.023). Eradication of the original serotype of group A streptococci was achieved in 91.3% of patients treated with cefprozil and 87.4% of patients treated with penicillin, the difference not being statistically significant (P = 0.125). However, there were significantly more symptomatic patients among the bacteriological failures in the penicillin group (68.4%) than in the cefprozil group (26.7%). 13-Lactamase-producing Staphylococcus aureus was more frequently isolated from the throat flora during penicillin therapy than during cefprozil treatment. No difference in the incidence of adverse events probably related or of unknown relationship to the study drugs was observed in the two treatment groups (5.2% of those treated with cefprozil and 6.0% of those treated with penicillin). Cefprozil can be considered a safe and reliable drug for the treatment of streptococcal pharyngitis in children.
Streptococcal tonsillopharyngitis is one of the most common bacterial infections in pediatric patients. Penicillin is still considered the drug of choice, although failure rates of up to 30% have been reported (7, 10, 12) . Since no penicillinresistant group A beta-hemolytic streptococci (GABHS) have been isolated, other reasons for the failure of therapy have been discussed, such as inactivation of penicillin by the P-lactamases produced by the concomitant throat flora or penicillin tolerance of the pathogen (2, 13, 14) .
Cephalosporins are stable to hydrolysis by the 1-lactamases of the bacteria that commonly colonize the mucous membranes of the upper respiratory tract. A meta-analysis of 19 different studies has shown that cephalosporins are more efficacious than penicillin in the treatment of streptococcal tonsillopharyngitis (19) .
Cefprozil is a new semisynthetic oral cephalosporin which has an in vitro spectrum that includes Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis (3, 6) . Its half-life of 1.3 h allows for once-or twice-daily dosing. In one comparative study, cefprozil was evaluated for the treatment of streptococcal pharyngitis in adults, and it was found to be as efficacious as cefaclor (4 (15) , which is based on the reduction of nutrients and enhancement of streptolysin S production. Thus, beta-hemolytic streptococci are easily recognized by their characteristic growth (very small colonies surrounded by a large hemolytic zone). The isolation rate of GABHS from throat swabs on this medium has been shown to be 5.5 to 11.6% higher than that on sheep blood agar (1, 16) . All plates were incubated aerobically overnight at 37°C in the physician's practice. Since only streptococci grow on streptococcal selective-elective agar, antibiotic treatment was initiated if beta-hemolytic colonies were detected. Both plates were sent to the central microbiology laboratory. Serogroups of the streptococcal isolates were determined by a latex agglutination test (Streptex; Oxoid). If GABHS were isolated from follow-up throat cultures, pre-and posttherapy isolates were serotyped by means of T-antigen agglutination and M-antigen precipitation, which were performed at the Zentralinstitut fur Mikrobiologie und Experimentelle Therapie in Jena, Germany. The presence of ,B-lactamase-producing S. aureus in the concomitant throat flora was investigated in 214 evaluable patients from the Munich area.
1-Lactamase production of the strains was tested by the nitrocefin method (20) .
Evaluation. Patients whose pretreatment cultures were positive for GABHS were eligible for evaluation of efficacy if the drug had been taken for at least 8 consecutive days and no other antimicrobial agents had been taken during the study period, i.e., during treatment and follow-up, and if at least one posttreatment evaluation had been performed.
Patients Five of the 15 homologous strains from patients treated with cefprozil were isolated at the first follow-up, and 10 recurred at the second follow-up, whereas 12 of the 19 penicillin V failures were detected at the first follow-up and 7 were detected at the last follow-up. In four patients treated with cefprozil, GABHS of a different serotype were isolated after the completion of therapy; two of these patients had symptoms of an infection. In the penicillin V group, five patients, two of whom were symptomatic, had positive follow-up cultures with a new serotype of GABHS.
There were significantly more symptomatic patients among the bacteriological failures in the penicillin group (13 of 19; 68.4%) than among those in the cefprozil group (4 of 15; 26.7%) (P = 0.037).
The presence of ,-laciamase-producing S. aureus in the concomitant throat flora was investigated in the 214 evaluable patients from Germany. During therapy, these bacteria were isolated more frequently from throat swabs of patients in the penicillin V group (13.0%) than from those of patients treated with cefprozil (4.5%) (P = 0.046). No difference was seen between the groups in the rate of isolation of 1-lactamase-producing S. aureus from pre-and posttherapy cultures (Table 3 ). In Table 4 , only those adverse effects considered to be probably related or of unknown relationship to the study drugs are summarized. Seven patients in the cefprozil group experienced 11 adverse events, and 12 patients in the penicillin V group experienced one adverse event each. The adverse events mainly originated from the gastrointestinal tract. No difference in the incidence of adverse effects was observed in the two treatment groups (5.2% in the cefprozil group and 6.0% in the penicillin group; P = 0.242). Because repeated laboratory tests were not mandatory, follow-up evaluations of blood chemistry and hematology were performed for only 15 patients in each treatment group.
No abnormal values were observed in any of these patients.
DISCUSSION
Cefprozil, a new semisynthetic oral cephalosporin, has in vitro activity superior to that of cefaclor against staphylococci, beta-hemolytic streptococci, and Streptococcuspneumoniae and is comparably active against H. influenzae and M. catarrhalis (3, 6) . Numerous comparative studies have shown that oral cephalosporins are more effective than or at least as effective as penicillin V for the treatment of streptococcal tonsillopharyngitis (5, 7, 9, 10, 11, 12, 18) . This was also confirmed by the results of our study. Cefprozil was clinically more effective than and bacteriologically as effective as penicillin V.
The bacteriological failure rate with cefprozil was 8.7%, which corresponds well to the figures reported in the literature for other cephalosporins such as cefalexin, cefadroxil, cefaclor, and cefuroxime axetil (5, 8, 9, 11, 18) , ranging between 2 and 10%. Although the failure rate for penicillin was somewhat higher than that for cefprozil, the difference was not statistically significant. A recently published metaanalysis has shown that in 16 of 19 comparative studies, the Table 3 , that cefprozil significantly reduced the isolation rate of S. aureus from the throat flora during therapy in comparison with penicillin (4.5 versus 13.0%).
The clinical outcomes for our patients treated with cefprozil were significantly better than those for patients who received penicillin. A satisfactory response was obtained in 95.3 and 88.1% of the patients, respectively. Interestingly, among those patients who were designated as bacteriological failures, 68.4% in the penicillin group were symptomatic, whereas only 26.7% in the cefprozil group were symptomatic.
Despite the repeatedly documented bacteriological or clinical superiority of the oral cephalosporins, penicillin V still remains the drug of choice because of its considerably lower price. On the other hand, one must consider the fact that the cephalosporins offer a variety of advantages, such as a better taste, which subsequently leads to better acceptance, and the possibility of once-or twice-daily dosing, which results in better compliance. In addition, it is obvious that more patients who are initially treated with penicillin must be retreated with another drug such as a cephalosporin, a macrolide, or clindamycin.
The results of our study indicate that cefprozil could be considered a safe and reliable drug for the treatment of streptococcal tonsillopharyngitis in children.
